Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial

Journal of the American Academy of Dermatology

Volumn 65, Issue 1, 2011, Pages

  Kuhn, Annegret ^a   Gensch, Kristina ^b   Haust, Merle ^b   Schneider, Stefan W ^c   Bonsmann, Gisela ^a   Gaebelein Wissing, Noemi ^d   Lehmann, Percy ^d   Wons, Annette ^a   Reitmeir, Peter ^e   Ruland, Vincent ^a   Luger, Thomas A ^a   Ruzicka, Thomas ^f  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HELIOS KLINIKUM WUPPERTAL   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

autoimmune disease; calcineurin inhibitors; cutaneous lupus erythematosus; randomized trial; tacrolimus ointment; treatment

Indexed keywords

ANTIVIRUS AGENT; TACROLIMUS;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSESTHESIA; ERYTHEMA; FEMALE; HERPES LABIALIS; HUMAN; MALE; MEDICAL PHOTOGRAPHY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN EDEMA; SKIN EXFOLIATION; SKIN HYPERTROPHY; SKIN LUPUS ERYTHEMATOSUS; SKIN PRURITUS; TREATMENT OUTCOME;

EID: 79958790928     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.03.037     Document Type: Article

References (36)

1. Kuhn A, Ruzicka T. Classification of cutaneous lupus eyrthematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer; 2004. pp. 53-8.
2. Lehmann P. Topical treatment of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Berlin: Springer; 2004. pp. 337-45.
3. Roenigk HH Jr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980;25:281-5.
4. Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol 2004;151:731-6. (Pubitemid 39482105)
5. Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 2008;6:48-59.
6. Werth V. Current treatment of cutaneous lupus erythematosus. Dermatol Online J 2001;7:2.
7. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001;(1).
8. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999;135:574-80.
9. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46: 228-41. (Pubitemid 34118380)
10. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55. (Pubitemid 34234209)
11. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46. (Pubitemid 34234208)
12. Langley RG, Luger TA, Cork MJ, Schneider D, Paul C. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007;215(Suppl. 1):27-44. (Pubitemid 350308378)
13. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008;159:942-51.
14. Hengge UR, Marini M. [Spezielle Behandlungsoptionen mit topischem Tacrolimus]. Stuttgart: Thieme; 2007.
15. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215(Suppl. 1):45-54. (Pubitemid 350308379)
16. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010;35:27-30.
17. Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007;156:191-2.
18. Sugano M, Shintani Y, Kobayashi K, Sakakibara N, Isomura I, Morita A. Successful treatment with topical tacrolimus in four cases of discoidlupus erythematosus. JDermatol 2006;33:887-91. (Pubitemid 44813793)
19. von Pelchrzim R, Schmook T, Friedrich M, Worm M. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. Int J Dermatol 2006; 45:84-5.
20. Meller S, Bruch-Gerharz D, Ruzicka T, Homey B. [Topical treatment of subacute-cutaneous lupus erythematosus with tacrolimus]. Hautarzt 2005;56:368-9, German.
21. Heffernan MP, Nelson MM, Smith DI, Chung JH. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol 2005;141:1170-1. (Pubitemid 41373975)
22. Druke A, Gambichler T, Altmeyer P, Freitag M, Kreuter A. 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 2004;15:63-4. (Pubitemid 38252101)
23. de la Rosa Carrillo D, Christensen OB. Treatment of chronic discoid lupus erythematosus with topical tacrolimus. Acta Derm Venereol 2004;84:233-4. (Pubitemid 38649406)
24. Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D'Cruz DP. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004;43:1383-5. (Pubitemid 39480924)
25. Bacman D, Tanbajewa A, Megahed M, Ruzicka T, Kuhn A. Topical treatment with tacrolimus in lupus erythematosus tumidus. Hautarzt 2003;54:977-9. (Pubitemid 37243390)
26. Bohm M, Gaubitz M, Luger TA, Metze D, Bonsmann G. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003;207:381-5. (Pubitemid 37505787)
27. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003;148:353-6. (Pubitemid 36278982)
28. Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002;147:405-6.
29. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002;12:50-2. (Pubitemid 34131138)
30. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009;34:776-80.
31. Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005;44:1564-8. (Pubitemid 41742477)
32. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Bader A, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407-10. (Pubitemid 39178668)
33. Zabawski E. Treatment of cutaneous lupus with Elidel. Dermatol Online J 2002;8:25.
34. Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31:185-98.
35. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
36. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)